Safety and Protective Efficacy of a Candidate Vector-Based Vaccine for Bovine Tuberculosis

Zhandos Abay, Ainur Nurpeisova, Kamshat Shorayeva, Sandugash Sadikaliyeva, Bolat Yespembetov, Nazym Syrymkyzy Syrym, Makhpal K. Sarmykova, Kuanysh Jekebekov, Ruslan Abitayev, Gaukhar Tokkarina

7 more authors

Elina Kalimolda, Zharkinay Absatova, S. U. Moldagulova, Han Sang Yoo, Markhabat Kassenov, Kunsulu D. Zakarya, Yergali O. Abduraimov

2023

Full text Open access: Gold Metadata (CSL-JSON)

DOI 10.3390/vaccines11071199

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

This study presents the results of a survey of the safety and protective efficacy of a candidate vector-based vaccine for bovine tuberculosis, using an influenza vector with the NS1 mutation and expressing M. bovis protective antigens ESAT-6 and TB10.4. We vaccinated Balb/c outbred mice two times at 21 days apart. Our experimental design includes mice immunised with the candidate vaccine with or without adjuvant 15% Montanide Gel. The candidate vaccine's safety was determined by biometric analysis, and protective efficacy was assessed by bacteriological and histological experiments following a virulent M. bovis-8 strain challenge. Our data indicated that the adjuvant-free version of the vaccine ensured complete protection from the M. bovis-8 infection in mice.